The latest news from Elumn8 Medical

Follow the progress of Elumn8 Medical (formerly known as Simpson Interventions)

Latest News

Feb 18, 2026

Simpson Interventions Announces Initial Close of Series C Financing and Corporate Rebrand to Elumn8 Medical

Series C financing supports continued clinical development of the Acolyte™ Image-Guided coronary chronic total occlusion (CTO) platform, an FDA Breakthrough Device; Company rebrands as Elumn8 Medical™ to better reflect expanded vision for image-enabled coronary interventions

Aug 14, 2025

Simpson Interventions Announces First Patients Treated in Clinical Trial for its Acolyte™ Catheter System

The first patients were treated at Emory University Hospital using the Acolyte Image-Guided Crossing and Re-Entry Catheter System...

Jan 7, 2025

Simpson Interventions Announces both IDE approval from FDA for Acolyte™ Catheter System and 510(k) clearance for its Shadow Catheter™, adds Board Member

Investigational Device Exemption (IDE) allows Acolyte™ System to be tested in clinical studies, a key step toward full clearance...

Jun 12, 2025

Simpson Interventions Announces Appointment of Dr. Joseph Knight as CEO

Prior CEO and Founder, Dr. John Simpson, to Remain with Company as Chief Medical Officer and Continue his Role as Chairman of the Board of Directors...

May 15, 2024

Simpson Interventions Accepted into FDA's TAP Pilot Program for Breakthrough Device, Acolyte™ Catheter System

This voluntary program is designed to help ensure U.S. patients have access to high-quality, safe, effective, and innovative medical devices by promoting early, frequent, and strategic communications between the FDA and medical device sponsors...

Apr 11, 2024

Simpson Interventions Receives FDA Breakthrough Device Designation for Acolyte™ Image Guided Crossing and Re-Entry Catheter System

Designation expedites the review of medical technologies that can improve the lives of patients with life-threatening or debilitating diseases or conditions...